Publications by authors named "Kevin R Porter"

Claim this Profile
M
Magnetoencephalography Reveals Neuroprotective Effects of COVID-19 Vaccination in Non-Human Primates.
Jennifer R Stapleton-Kotloski, Jared A Rowland, April T Davenport, Phillip M Epperly, Maria Blevins, Kevin R Porter

bioRxiv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and Protective Efficacy of Psoralen-Inactivated SARS-CoV-2 Vaccine in Nonhuman Primates.
John W Sanders, Daniel Ewing, Appavu K Sundaram, Christopher Scott Gamble, Maria Blevins, Kevin R Porter

Vaccines (Basel)· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etiologies of Acute Undifferentiated Febrile Illnesses in and near Iquitos from 1993 to 1999 in the Amazon River Basin of Peru.
Douglas M Watts, Kevin L Russell, Mark T Wooster, Trueman W Sharp, Amy C Morrison, Kevin R Porter

Am J Trop Med Hyg· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pseudovirus-Based Assays for the Measurement of Antibody-Mediated Neutralization of SARS-CoV-2.
Corey Balinsky, Vihasi Jani, Peifang Sun, Maya Williams, Gabriel Defang, Kevin R Porter

Methods Mol Biol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced Immunogenicity of Inactivated Dengue Vaccines by Novel Polysaccharide-Based Adjuvants in Mice.
Shuenn-Jue Wu, Dan Ewing, Appavu K Sundaram, Hua-Wei Chen, Zhaodong Liang, Kevin R Porter

Microorganisms· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice.
Appavu K Sundaram, Daniel Ewing, Zhaodong Liang, Vihasi Jani, Ying Cheng, Kevin R Porter

Pathogens· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands.
Guy El Helou, Todd A Ponzio, Joseph F Goodman, Maria Blevins, David L Caudell, Kevin R Porter

Trop Dis Travel Med Vaccines· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of purified psoralen-inactivated and formalin-inactivated dengue vaccines in mice and nonhuman primates.
Appavu K Sundaram, Daniel Ewing, Maria Blevins, Zhaodong Liang, Sandy Sink, Kevin R Porter

Vaccine· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced immunogenicity and protective efficacy of a tetravalent dengue DNA vaccine using electroporation and intradermal delivery.
Maya Williams, Dan Ewing, Maria Blevins, Peifang Sun, Appavu K Sundaram, Kevin R Porter

Vaccine· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial.
Janine R Danko, Tadeusz Kochel, Nimfa Teneza-Mora, Thomas C Luke, Kanakatte Raviprakash, Kevin R Porter

Am J Trop Med Hyg· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA Vaccine Delivery and Improved Immunogenicity.
Kevin R Porter, Kanakatte Raviprakash

Curr Issues Mol Biol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NK cell degranulation as a marker for measuring antibody-dependent cytotoxicity in neutralizing and non-neutralizing human sera from dengue patients.
Peifang Sun, Brian J Morrison, Charmagne G Beckett, Zhaodong Liang, Nishith Nagabhushana, Kevin R Porter

J Immunol Methods· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Epidemiology, Virology and Clinical Findings of Dengue Virus Infections in a Cohort of Indonesian Adults in Western Java.
Herman Kosasih, Bachti Alisjahbana, Nurhayati, Quirijn de Mast, Irani F Rudiman, Kevin R Porter

PLoS Negl Trop Dis· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nucleic acid (DNA) immunization as a platform for dengue vaccine development.
Kevin R Porter, Kanakatte Raviprakash

Vaccine· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tetravalent DNA vaccine product as a vaccine candidate against dengue.
Kevin R Porter, Nimfa Teneza-Mora, Kanakatte Raviprakash

Methods Mol Biol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence for endemic chikungunya virus infections in Bandung, Indonesia.
Herman Kosasih, Quirijn de Mast, Susana Widjaja, Primal Sudjana, Ungke Antonjaya, Kevin R Porter

PLoS Negl Trop Dis· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine.
Kevin R Porter, Daniel Ewing, Lan Chen, Shuenn-Jue Wu, Curtis G Hayes

Vaccine· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of dengue DNA vaccines.
Janine R Danko, Charmagne G Beckett, Kevin R Porter

Vaccine· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys.
Ryan C Maves, Roger M Castillo Oré, Kevin R Porter, Tadeusz J Kochel

Vaccine· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial.
Charmagne G Beckett, Jeffrey Tjaden, Timothy Burgess, Janine R Danko, Cindy Tamminga, Kevin R Porter

Vaccine· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice.
Ryan C Maves, Roger M Castillo Oré, Kevin R Porter, Tadeusz J Kochel

Clin Vaccine Immunol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional characterization of ex vivo blood myeloid and plasmacytoid dendritic cells after infection with dengue virus.
Peifang Sun, Stefan Fernandez, Mary A Marovich, Dupeh R Palmer, Christina M Celluzzi, Kevin R Porter

Virology· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector.
Nicholas U Raja, David H Holman, Danher Wang, Kanakatte Raviprakash, Laure Y Juompan, Kevin R Porter

Am J Trop Med Hyg· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes.
David H Holman, Danher Wang, Kanakatte Raviprakash, Nicholas U Raja, Min Luo, Kevin R Porter

Clin Vaccine Immunol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Needle-free injection of DNA vaccines: a brief overview and methodology.
Kanakatte Raviprakash, Kevin R Porter

Methods Mol Med· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis